{"groups":[{"description":"Patients received IV cisplatin 25 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4, gemcitabine 1000 mg/m2 day 1 and solumedrol 250 mg days 1-4 of a 21 day cycle for 6 cycles.","id":"FG000","title":"PEGS"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"not protocol specified"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"not eligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"Eligible"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"Eligible and Began Protocol Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}